Hantz Financial Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Hantz Financial Services’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-178	Closed	-$9K	–	2187
2025 Q1	$9K	Hold	178	–	–	﹤0.01%	983
2024 Q4	$9K	Hold	178	–	–	﹤0.01%	822
2024 Q3	$11K	Hold	178	–	–	﹤0.01%	782
2024 Q2	$11K	Hold	178	–	–	﹤0.01%	788
2024 Q1	$10K	Hold	178	–	–	﹤0.01%	824
2023 Q4	$10K	Hold	178	–	–	﹤0.01%	801
2023 Q3	$9K	Hold	178	–	–	﹤0.01%	809
2023 Q2	$9K	Hold	178	–	–	﹤0.01%	789
2023 Q1	$10K	Hold	178	–	–	﹤0.01%	774
2022 Q4	$10K	Hold	178	–	–	﹤0.01%	749
2022 Q3	$8K	Hold	178	–	–	﹤0.01%	769
2022 Q2	$9K	Hold	178	–	–	﹤0.01%	754
2022 Q1	$11K	Buy	+178	New	+$10.9K	﹤0.01%	773

Other funds holding BIB

CIC

Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return

WWM

Westwood Wealth Management Los Angeles, California $345M AUM 113.04% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PSFG

Park Square Financial Group Roswell, Georgia $11.1M AUM 15.3% 1-Year Est. Return

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Garde Capital Seattle, Washington $2.23B AUM 16.29% 1-Year Est. Return

Hantz Financial Services's BIB Position: Q2 2025 in Review

Hantz Financial Services sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2025, closing a stake of 178 shares — an estimated $9K sold.

Hantz Financial Services first reported a position in BIB in Q1 2022 and held it in 13 quarters. The position peaked at $11K in Q3 2024. 17 funds tracked by Wall St. Rank hold BIB as of Q2 2025.

Hantz Financial Services reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2025 after selling out during the quarter.
Hantz Financial Services sold 178 ProShares Ultra NASDAQ Biotechnology shares in Q2 2025, an estimated $9K.
Hantz Financial Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2022 and held it in 13 quarters.
Hantz Financial Services's ProShares Ultra NASDAQ Biotechnology position peaked at $11K in Q3 2024.
17 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2025.

Based on Hantz Financial Services's 13F filing for Q2 2025, filed 4 Aug 2025.